Market Access News | pharmaphorum

News

woman suffering from uterine fibroid pain holding her abdomen

Theramex's uterine fibroid drug Yselty backed for NHS use

A daily oral therapy for uterine fibroids has been recommended for NHS by NICE, providing a new option for around 30,000 women in England and Wales.

News

Rachel Reeves appointed as Chancellor of the Exchequer by Keir Starmer, 5th July 2024

AstraZeneca said to be wavering on £450m UK vaccine plant

AstraZeneca's plan to invest £450 million ($578 million) in a vaccines manufacturing plant in the UK has been thrown into doubt, claims a report in the Financial Times.

News

AZ gets landmark approval for Imfinzi/Lynparza combo

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.

News

prescription digital therapeutic on a smartphone

Otsuka, Click's depression DTx launches in the US

An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.

News

Galderma's chief executive Flemming Ørnskov

Galderma gets FDA nod for prurigo nodularis therapy

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales.

News

Create Health Ventures managing partners Amit Aysola and Emma Cartmell

Digital health fund makes debut with $21m for start-ups

A group of healthcare industry veterans have launched a new investment fund – called Create Health Ventures – with $21 million in the pot to support early-stage companies with tech that can

Theramex's uterine fibroid drug Yselty backed for NHS use

AstraZeneca said to be wavering on £450m UK vaccine plant

AZ gets landmark approval for Imfinzi/Lynparza combo

Otsuka, Click's depression DTx launches in the US

Galderma gets FDA nod for prurigo nodularis therapy

Digital health fund makes debut with $21m for start-ups

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks